Drug Type Antibody–siRNA conjugates (ARC) |
Synonyms TM4SF1 - siRNA ARC(Tavotek) |
Target |
Action inhibitors |
Mechanism MYC inhibitors(Myc proto-oncogene protein inhibitors), TM4SF1 inhibitors(transmembrane 4 L six family member 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | Preclinical | United States | 28 Apr 2025 | |
Lung Cancer | Preclinical | China | 28 Apr 2025 | |
Pancreatic Cancer | Preclinical | United States | 28 Apr 2025 | |
Pancreatic Cancer | Preclinical | China | 28 Apr 2025 | |
Stomach Cancer | Preclinical | United States | 28 Apr 2025 | |
Stomach Cancer | Preclinical | China | 28 Apr 2025 |